Examples of 'eltrombopag' in a sentence
Meaning of "eltrombopag"
Eltrombopag is a noun that refers to a medication used to treat thrombocytopenia, typically found in medical contexts
Show more definitions
- A drug to treat conditions that lead to thrombocytopenia.
How to use "eltrombopag" in a sentence
Basic
Advanced
eltrombopag
Revolade contains the active substance eltrombopag.
Use lowest dose of eltrombopag to maintain platelet counts.
Eltrombopag must not be used to normalise platelet counts.
Revolade is medicine that contains the active substance eltrombopag.
Effects of eltrombopag on other medicinal products.
Bleeding following discontinuation of eltrombopag.
Absorbed eltrombopag is extensively metabolised.
Loss of response to eltrombopag.
Eltrombopag dose once daily.
Exercise caution when administering eltrombopag to patients with hepatic disease.
Eltrombopag dose may need to be increased based on these platelet counts.
Caution is required when administering eltrombopag to patients with hepatic disease.
Eltrombopag should be terminated if antiviral therapy is discontinued for hepatic decompensation.
The objective of treatment with eltrombopag should not be to normalise platelet counts.
Eltrombopag is also under.
See also
The active substance in Revolade is eltrombopag.
Use lowest dose of eltrombopag as necessary to avoid dose reductions of peginterferon.
Thrombocytopenia is likely to reoccur in ITP patients upon discontinuation of treatment with eltrombopag.
The dose of eltrombopag could be adjusted based on individual platelet counts.
In ITP and SAA patients a lower starting dose of eltrombopag should be used.
The lowest dose of eltrombopag needed to achieve the targets should be used.
What Revolade contains The active substance in Revolade is eltrombopag.
Eltrombopag treatment delayed and reduced the number of peginterferon dose reductions.
Platelet counts must be monitored weekly for 4 weeks following discontinuation of eltrombopag.
Eltrombopag treatment should be terminated when antiviral therapy is discontinued unless otherwise justified.
The median time to diagnosis was 3 months from the start of eltrombopag treatment.
The safety and efficacy of eltrombopag in paediatric subjects has been investigated in two studies.
The primary endpoint was haematological response assessed after 12 weeks of eltrombopag treatment.
Eltrombopag is highly coloured and so has the potential to interfere with some laboratory tests.
Dose adjustment is not required when eltrombopag is co-administered with either telaprevir or boceprevir.
Eltrombopag was an inhibitor of a number of UGT enzymes in vitro.
In clinical studies, platelet counts generally began to increase within 1 week of starting eltrombopag.
Discontinue Eltrombopag olamine if antiviral therapy is discontinued.
Platelet counts were increased during treatment with eltrombopag and for up to 2 weeks after treatment.
Eltrombopag can be administered in addition to other ITP medicinal products.
Table 3 Dose adjustments of eltrombopag in patients with severe aplastic anaemia.
Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals.
The primary endpoint was hematologic response assessed after 12 weeks of treatment with Eltrombopag olamine.
I, eltrombopag may be reinitiated at the previous effective dose.
Table 2 Dose adjustments of eltrombopag in HCV patients during antiviral therapy.
Eltrombopag was discontinued after 16 weeks if no haematological response or transfusion independence was observed.
In vitro studies demonstrated that eltrombopag is a breast cancer resistance protein ( BCRP ) substrate and inhibitor.
Eltrombopag dosing requirements must be individualised based on the patient 's platelet counts.
The pharmacokinetic parameters of eltrombopag in paediatric subjects with ITP are shown in Table 10.
Eltrombopag is primarily metabolised through cleavage, oxidation and conjugation with glucuronic acid, glutathione, or cysteine.
The pharmacokinetic parameters of eltrombopag in paediatric patients with ITP are shown in Table 10.
Eltrombopag administration can cause abnormal liver function and severe hepatotoxicity, which might be life-threatening.
Table 1 Dose adjustments of eltrombopag in ITP patients.
Co-administration of eltrombopag with lopinavir / ritonavir may cause a decrease in the concentration of eltrombopag.
All patients initiated treatment with eltrombopag 50 mg.
